Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis

Ítems similars

• A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
  per: Campa, Molly, et al.
  Publicat: (2015)
• New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
  per: Gaspari, Anthony A, et al.
  Publicat: (2015)
• Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
  Publicat: (2021)
• Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
  per: Frieder, Jillian, et al.
  Publicat: (2017)
• IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
  per: Shi, Yuling, et al.
  Publicat: (2019)